NCT06955208 3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features
| NCT ID | NCT06955208 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shengjing Hospital |
| Condition | Meningioma |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2022-10-19 |
| Primary Completion | 2026-10-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2022-10-19 with a primary completion date of 2026-10-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective single-center study aims to evaluate the feasibility and clinical utility of three-dimensional magnetic resonance elastography (3D MRE) in assessing tumor stiffness and adhesion in patients with meningioma undergoing surgical resection. By correlating preoperative MRE-derived stiffness and adhesion maps with intraoperative findings and histopathological features, the study seeks to determine whether MRE can serve as a noninvasive imaging biomarker for surgical planning, risk stratification, and prediction of tumor behavior.
Eligibility Criteria
Inclusion Criteria: * All patients undergoing meningeoma resection surgery are eligible for inclusion in the study cohort. Exclusion Criteria: * Patients with metallic implants or foreign bodies in their bodies (pacemakers, artificial metallic heart valves, metal joints, metal implants, and those who can not remove dentures, insulin pumps, or contraceptive rings) * Pregnant women in the first trimester (within three months) * Patients with severe claustrophobia or anxiety * Patients with severe fever * Patients who can not tolerate MRE * Patients with vascular malformations and aneurysms. * Patients who do not sign an informed consent
Contact & Investigator
Yu Shi, MD
PRINCIPAL INVESTIGATOR
Shengjing Hospital
Frequently Asked Questions
Who can join the NCT06955208 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Meningioma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06955208 currently recruiting?
Yes, NCT06955208 is actively recruiting participants. Contact the research team at 18940259980@163.com for enrollment information.
Where is the NCT06955208 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT06955208 clinical trial?
NCT06955208 is sponsored by Shengjing Hospital. The principal investigator is Yu Shi, MD at Shengjing Hospital. The trial plans to enroll 300 participants.